Kiat Ruxrungtham Selected Research

Reverse Transcriptase Inhibitors

7/2020	Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
1/2014	Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand.
10/2012	Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
1/2011	Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
4/2009	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
3/2005	Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
1/2005	Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
9/2003	Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kiat Ruxrungtham Research Topics

Disease

32	Infections 11/2023 - 09/2003
23	Coinfection 01/2021 - 10/2003
15	HIV Infections (HIV Infection) 07/2020 - 06/2004
14	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 12/2008
11	Tuberculosis (Tuberculoses) 01/2022 - 01/2005
9	Viremia 01/2023 - 06/2004
9	Body Weight (Weight, Body) 06/2019 - 05/2003
9	Hypersensitivity (Allergy) 03/2018 - 06/2006
5	Dengue (Dengue Fever) 11/2023 - 01/2014
5	Allergic Rhinitis 01/2021 - 09/2003
5	Hepatitis B 09/2020 - 03/2002
5	Fibrosis (Cirrhosis) 09/2014 - 09/2008
4	COVID-19 03/2024 - 07/2021
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 09/2008
4	Schizophrenia (Dementia Praecox) 06/2018 - 01/2017
4	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2008 - 09/2003
3	Disease Progression 01/2018 - 05/2004
3	Asthma (Bronchial Asthma) 01/2016 - 06/2002
3	Liver Diseases (Liver Disease) 09/2014 - 09/2008
3	Exanthema (Rash) 07/2011 - 01/2005
2	Obstructive Sleep Apnea 09/2023 - 12/2014
2	Virus Diseases (Viral Diseases) 12/2021 - 06/2015
2	Diabetes Mellitus 01/2021 - 01/2017
2	Hepatitis C 09/2020 - 09/2014
2	Human Influenza (Influenza) 01/2020 - 11/2019
2	Lipodystrophy 01/2017 - 01/2015
2	Opportunistic Infections (Opportunistic Infection) 01/2016 - 01/2015
2	Anaphylaxis (Anaphylactic Shock) 03/2015 - 12/2010
2	Hepatitis 05/2013 - 05/2004
2	Dizziness (Lightheadedness) 07/2011 - 01/2010
1	Rhinitis 09/2023
1	Leptospirosis 01/2022
1	Severe Dengue 09/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2020
1	Syphilis 01/2020
1	Atherosclerosis 11/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019

Drug/Important Bio-Agent (IBA)

11	RNA (Ribonucleic Acid)IBA 09/2021 - 05/2004
10	VaccinesIBA 03/2024 - 10/2010
10	Tenofovir (Viread)FDA Link 06/2019 - 01/2008
9	NucleosidesIBA 07/2020 - 09/2003
8	DNA (Deoxyribonucleic Acid)IBA 09/2020 - 09/2008
8	Reverse Transcriptase InhibitorsIBA 07/2020 - 09/2003
8	efavirenz (Sustiva)FDA Link 01/2016 - 01/2005
8	Ritonavir (Norvir)FDA Link 01/2016 - 05/2003
8	Rifampin (Rifampicin)FDA LinkGeneric 10/2012 - 01/2005
6	Stavudine (Zerit)FDA LinkGeneric 01/2021 - 06/2004
6	Nevirapine (Viramune)FDA Link 06/2011 - 01/2005
5	Protease Inhibitors (Protease Inhibitor)IBA 01/2016 - 03/2007
5	AntigensIBA 09/2015 - 03/2005
5	Rilpivirine (TMC-278)IBA 01/2014 - 01/2010
5	Hepatitis B e AntigensIBA 01/2014 - 09/2008
5	Lamivudine (Epivir)FDA Link 03/2012 - 09/2005
4	Neutralizing AntibodiesIBA 03/2024 - 01/2014
4	Tryptophan (L-Tryptophan)FDA Link 06/2018 - 01/2017
4	DNA VaccinesIBA 03/2017 - 03/2013
4	Alanine Transaminase (SGPT)IBA 09/2014 - 01/2005
3	Lipopolysaccharide ReceptorsIBA 09/2020 - 03/2011
3	N-acetyltalosaminuronic acid (NAT)IBA 09/2020 - 05/2004
3	Antiviral Agents (Antivirals)IBA 01/2020 - 04/2007
3	Immunoglobulin A (IgA)IBA 01/2018 - 01/2017
3	AllergensIBA 09/2014 - 09/2003
3	Indinavir (Crixivan)FDA Link 10/2012 - 05/2003
3	LipidsIBA 07/2011 - 03/2007
2	AntibodiesIBA 11/2023 - 09/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2023 - 01/2016
2	SteroidsIBA 09/2023 - 12/2014
2	EpitopesIBA 01/2023 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 09/2020 - 05/2013
2	Hemoglobins (Hemoglobin)IBA 09/2020 - 07/2013
2	Oseltamivir (Tamiflu)FDA Link 01/2020 - 11/2019
2	Immunoglobulin M (IgM)IBA 01/2018 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 09/2015 - 09/2008
2	Atazanavir Sulfate (Reyataz)FDA Link 05/2015 - 12/2013
2	Interleukin-10 (Interleukin 10)IBA 09/2014 - 05/2013
2	Vitamin D FDA LinkGeneric 09/2014 - 01/2014
2	etravirine (TMC-125)FDA Link 01/2014 - 01/2011
2	Emtricitabine (Emtriva)FDA Link 01/2010 - 01/2008
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 03/2005 - 09/2003
1	mRNA VaccinesIBA 01/2024
1	ChulaCov19 vaccineIBA 01/2023
1	Subunit VaccinesIBA 01/2022
1	SaponinsIBA 01/2022
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2022
1	Double-Stranded RNA (RNA, Double Stranded)IBA 12/2021
1	HDL LipoproteinsIBA 01/2021
1	Interleukin-7 (Interleukin 7)IBA 09/2020
1	NucleotidesIBA 07/2020
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2020
1	C-Reactive ProteinIBA 11/2019
1	HIV hyperimmune globulinIBA 11/2019
1	Intravenous Immunoglobulins (IVIG)FDA Link 11/2019
1	CobicistatIBA 06/2019
1	elvitegravirIBA 06/2019
1	emtricitabine tenofovir alafenamideIBA 06/2019
1	Antitubercular AgentsIBA 03/2018

Therapy/Procedure

33	Therapeutics 01/2022 - 09/2003
13	Art Therapy 01/2023 - 01/2005
13	Highly Active Antiretroviral Therapy (HAART) 01/2017 - 05/2004
3	Immunotherapy 01/2021 - 09/2014